Baader Bank Aktiengesellschaft Makes New $1.73 Million Investment in Guardant Health, Inc. $GH

Baader Bank Aktiengesellschaft acquired a new stake in shares of Guardant Health, Inc. (NASDAQ:GH) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 16,900 shares of the company’s stock, valued at approximately $1,726,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Emerald Advisers LLC boosted its holdings in shares of Guardant Health by 24.8% in the 3rd quarter. Emerald Advisers LLC now owns 873,203 shares of the company’s stock valued at $54,558,000 after buying an additional 173,281 shares in the last quarter. Knights of Columbus Asset Advisors LLC acquired a new stake in shares of Guardant Health during the 3rd quarter worth approximately $1,554,000. Universal Beteiligungs und Servicegesellschaft mbH grew its stake in shares of Guardant Health by 54.4% during the 3rd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 301,449 shares of the company’s stock worth $18,835,000 after purchasing an additional 106,263 shares during the period. Erste Asset Management GmbH grew its stake in Guardant Health by 10.4% in the 3rd quarter. Erste Asset Management GmbH now owns 705,217 shares of the company’s stock valued at $43,716,000 after acquiring an additional 66,617 shares during the period. Finally, Segall Bryant & Hamill LLC grew its stake in Guardant Health by 57.8% in the 3rd quarter. Segall Bryant & Hamill LLC now owns 305,147 shares of the company’s stock valued at $19,066,000 after acquiring an additional 111,822 shares during the period. 92.60% of the stock is owned by hedge funds and other institutional investors.

Guardant Health Trading Down 1.5%

Shares of GH opened at $98.47 on Thursday. The firm has a market cap of $13.06 billion, a P/E ratio of -29.05 and a beta of 1.48. Guardant Health, Inc. has a 12-month low of $36.36 and a 12-month high of $120.74. The company’s 50-day moving average price is $89.16 and its 200 day moving average price is $97.74.

Guardant Health (NASDAQ:GH) last released its earnings results on Thursday, February 19th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.07). The business had revenue of $281.27 million during the quarter, compared to the consensus estimate of $269.74 million. Guardant Health’s quarterly revenue was up 39.4% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.62) earnings per share. Equities research analysts forecast that Guardant Health, Inc. will post -2.87 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on GH shares. Robert W. Baird assumed coverage on shares of Guardant Health in a research note on Tuesday, February 17th. They set an “outperform” rating and a $120.00 target price on the stock. Citigroup lifted their price target on Guardant Health from $135.00 to $150.00 and gave the stock a “buy” rating in a report on Friday, February 20th. Leerink Partners lifted their price target on Guardant Health from $170.00 to $180.00 and gave the stock an “outperform” rating in a report on Friday, February 20th. Stifel Nicolaus lifted their price target on Guardant Health from $120.00 to $130.00 and gave the stock a “buy” rating in a report on Friday, February 20th. Finally, Raymond James Financial reiterated an “outperform” rating and set a $129.00 price target on shares of Guardant Health in a report on Monday, February 23rd. Nineteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Guardant Health presently has an average rating of “Moderate Buy” and an average target price of $129.42.

Insider Buying and Selling

In other news, insider Terilyn J. Monroe sold 3,832 shares of the business’s stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $92.68, for a total transaction of $355,149.76. Following the completion of the transaction, the insider directly owned 20,990 shares of the company’s stock, valued at approximately $1,945,353.20. The trade was a 15.44% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Musa Tariq sold 348 shares of the business’s stock in a transaction dated Wednesday, March 18th. The stock was sold at an average price of $88.09, for a total value of $30,655.32. Following the transaction, the director directly owned 8,394 shares of the company’s stock, valued at approximately $739,427.46. This represents a 3.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 58,596 shares of company stock worth $5,791,767 over the last 90 days. 5.60% of the stock is owned by insiders.

Guardant Health Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.